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Clinical trials increasingly incorporate suicide genes either as direct lytic agents for tumors or
as safety switches in therapies based on genetically modiﬁed cells. Suicide genes can also
be used as non-invasive reporters to monitor the biological consequences of administering
genetically modiﬁed cells to patients and gather information relevant to patient safety.These
genes can monitor therapeutic outcomes addressable by early clinical intervention. As
an example, our recent clinical trial used 18 F-9-(4-ﬂuoro-3-hydroxymethylbutyl)guanine
(18 FHBG) and positron emission tomography (PET)/CT scans to follow T cells transduced
with herpes simplex virus thymidine kinase after administration to patients. Guided by
preclinical data we ultimately hope to discern whether a particular pattern of transduced T
cell migration within patients reﬂects early development of graft vs. host disease. Current
difﬁculties in terms of choice of suicide gene, biodistribution of radiolabeled tracers in
humans vs. animal models, and threshold levels of genetically modiﬁed cells needed for
detection by PET/CT are discussed. As alternative suicide genes are developed, additional
radiolabel probes suitable for imaging in patients should be considered.
Keywords: suicide gene, gene therapy, thymidine kinase, PET-imaging, transplant biology, regenerative medicine

CLINICAL SAFETY SWITCHES
Suicide genes convert innocuous prodrugs into cytotoxic products.
Injecting viruses carrying suicide genes directly into solid tumors
destroys the virus-infected cells and nearby neighbors through diffusion of cytotoxic products. Inserting suicide genes into cells that
migrate to tumors [autologous tumor cells, mesenchymal stem
cells, neural stem cells, and immune cells such as T cells, NK cells,
and genetically modiﬁed chimeric antigen receptor T (CAR-T)
cells] can accomplish the same task.
Leukemia patients are often administered allogeneic T cells to
attack their cancerous cells. Unfortunately T cell replete transplants with the most robust anti-tumor activity tend to have the
greatest potential to cause graft vs. host disease (GvHD), a frequent
and sometimes fatal side effect of allogeneic stem cell transplantation. GvHD manifests itself early after transplantation and after
the overt elimination of leukemia. T cells genetically modiﬁed
to express the herpes simplex virus thymidine kinase (TK) suicide
gene can be killed by administering the prodrug ganciclovir (GCV)
to induce apoptosis at the ﬁrst sign of GvHD (Mercier-Letondal
et al., 2008; Zhan et al., 2013). Although CAR-T cells provide a
more targeted type of T cell mediated anti-tumor therapy, the
potential for GvHD or some off-target tissue damage is not eliminated and the need for a suicide gene safety switch cannot be
underestimated.
Safety switches (suicide genes) are of particular value in
therapies dependent upon long-lived and/or proliferating cells.
Genetically modiﬁed cells carry an inherent and potentially lifelong hazard of cancerous transformations. Stem cells administered
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to regenerate tissues damaged by disease or treatment, correct
congenital malformations, or rejuvenate aging tissues may have
unknown risks (Mavroudi et al., 2014). Likewise there could be
unintended consequences from administering autologous cells
modiﬁed ex vivo to act as in-patient factories to produce biological molecules, such as insulin, to alleviate the need for repeated
injections (Sanlioglu et al., 2012).

REPORTERS TO MONITOR CLINICAL SAFETY AND BIOLOGY
Monitoring the location of genetically modiﬁed cells in patients
could have important ramiﬁcations in terms of either safety or
the general biology of these therapeutic interventions. Do the cells
reach their target or migrate to an unexpected location, cause damage to a normal tissue, or contribute to tumor progression? If a
cancer relapses, do modiﬁed immune cells reactivate, proliferate,
and target the new tumor or ignore it? Is an organ regenerated primarily from genetically modiﬁed stem cells recruited to enhance
tissue repair? What is the relative amount of modiﬁed cells at various sites? Do ex vivo manipulations of transduced cells affect their
therapeutic potential and biodistribution? The limited penetration of visible light through human and large animal bodies makes
answering these questions by tagging the cells with bioluminescent
reporter probes (luciferase) untenable. Also, there are no Food and
Drug Administration (FDA) approved reagents for generation and
measurement of bioluminescent imaging in humans. In these situations higher energy reporters are needed, such as those suitable
for imaging via positron emission tomography (PET) scans of
patients.
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HERPES SIMPLEX VIRUS THYMIDINE KINASE
All enzyme-based suicide genes should amplify tracer signals,
but to be a successful reporter the product of the reaction must
also be retained in the cells. Conversion of 5-ﬂuorocytosine
by cytosine deaminase to a molecule that diffuses out of the
cell, 5-ﬂuorouracil, makes it a poor reporter. In contrast TK
phosphorylates cellular substrates (ganciclovir, penciclovir, and
derivatives) into membrane impermeable phosphorylated forms
and entraps them within cells. This makes TK a better choice for
imaging studies.
Following administration of a cationic liposomal vector carrying the suicide gene in an expression plasmid, TK was ﬁrst
monitored in ﬁve glioblastoma patients using the substrate 124 Ilabeled 2 -ﬂuoro-2 -deoxy-1β-D-arabino-furanosyl-5-iodo-uracil
(124 I-FIAU; Jacobs et al., 2001). 124 I-FIAU-PET imaging detected
a brain tumor in only one of the patients. Since histology indicated that there were signiﬁcantly fewer cells in the tumors of the
remaining four patients, the authors theorized that a threshold
number of labeled cells must be present before 124 I-FIAU-PET
scans can detect them.
A later study used 9-[4-[18 F]ﬂuoro-3-(hydroxymethyl)butyl]
guanine (18 F-FHBG) as a substrate for TK (Penuelas et al., 2005).
The enzyme was carried by an adenovirus injected directly into
liver tumors. The tumors were visible by 18 F-FHBG–PET in the
initial scan before a 2-week valganciclovir treatment was begun
only in patients receiving a threshold of ≥1012 virus particles, and
disappeared by day 7 of treatment.
In 2009 cells were ﬁrst modiﬁed ex vivo to carry a suicide gene
as both a safety switch and a reporter in patients (Yaghoubi et al.,
2009). An IL-13 zetakine gene was included to improve tumor
targeting by autologous CD8+ T cells, and a single patient was
evaluated. 18 F-FHBG–PET imaging successfully localized the T
cells to both a resected glioma and an adjacent tumor that had
formed after the resection.
Our own recently completed trial, to be reported in detail
elsewhere (Infusion of genetically modiﬁed T cells: a pilot
study of tracking and toxicity, IND 11917, clinicaltrials.gov
#NCT00871702), is the only additional clinical study of which
we are aware that uses 18 F-FHBG–PET to follow TK-modiﬁed
cells. Allogeneic donor T cells were retrovirally transduced to
carry a TK-based suicide gene both as a means of controlling
GvHD and to facilitate tracking of their migration in patients
undergoing a donor lymphocyte infusion (DLI). To achieve both
greater sensitivity to GCV and more accumulation of the phosphorylated 18 F-FHBG for imaging, we used, TK75, a hyperactive
mutated version of the enzyme (Black et al., 1996). TK75 was
fused to the extracellular and transmembrane domains of the
human CD34 protein (CD34-TK75) to facilitate selection of transduced cells using a Miltenyi CliniMACS CD34 reagent system
during manufacturing and detection of the cells by ﬂow cytometry both during production and in the peripheral blood of
patients.
Our preclinical bioluminescence studies suggested that allogeneic T cells migrate in a distinctive pattern when they cause
GvHD in mice (Nervi et al., 2007). Finding such a pattern in
patients could provide both a non-invasive means to track these
cells in human DLI recipients and a surrogate marker to predict
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which patients are most likely to develop GvHD. In our phase I
study the ﬁrst two patients who received puriﬁed CD34-TK75transduced cells as a DLI had no correlative 18 F-FHBG-PET/CT
imaging. The remaining six individuals were scanned at three time
points. Because in a DLI setting acute GvHD is usually not evident before 30 days post administration of T cells, we chose to do
one baseline scan before the DLI, and additional scans on ∼days
+14 and +30 after the infusion of the CD34-TK75 genetically
modiﬁed DLI.
Only one of our six imaged patients developed GvHD (day
64) potentially attributable to the genetically modiﬁed T cells.
Unfortunately no discernable difference was observed between
the biodistribution of 18 F-FHBG in this or any other patient at
baseline and later time points (Figure 1). We used a portion of
the same CD34-TK75 transduced donor T cells and 18 F-FHBG
prepared for the patients under GMP conditions in a parallel
transplant of 2 NOD-SCIDg-/-(NSG) mice for each patient. As
expected the xenogeneic CD34-TK75 transduced T cells induced
GvHD in NSG mice, and the 18 F-FHBG-microPET/CT scans
revealed transduced T cells in their thymic region (Figure 2).
We previously demonstrated by BLI that this site is one of the
preferred locations for migration and expansion of human T
cells during xenogeneic GvHD (Nervi et al., 2007). Our current data recapitualted this distinctive migration pattern and also
reﬂects the feasibility of in-house cGMP production of both functional transduced suicide gene expressing human T cells and
18 F-FHBG.
Data from other trials suggested that the therapeutic potential
of T cells is affected by the means in which T cells are activated pretransduction and the method of expansion thereafter (review Cieri
et al., 2014). Our cells were activated with IL2 and anti-CD3/antiCD28 coated beads, and expanded for only 2–3 days prior to
infusion into patients. While the cells functioned as expected in
our xenograft model and persisted for at least 6 months (latest time
point evaluated), it is possible that their function was sub-optimal
in patients. Including HSV-TK as a reporter in future studies
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FIGURE 1 | 18 F-FHBG-PET/CT scans of patients. Under FDA IND #11917
(clinicaltrials.gov #NCT00871702) patients received 0.1–1.3 × 106 puriﬁed
allogeneic CD34-TK75-transduced cells/kg as a donor lymphocyte infusion
(DLI). 18 F-FHBG-PET/CT scans were performed at baseline before DLI, and
on ∼days +14 and +30 after DLI. Anterior and posterior reprojection images
of patient TK05 are shown. Scans were made 60 min after administration of
18 F-FHBG and show a normal distribution of the radiotracer. No
reproducible difference was detected between the baseline and later scans
for any patient. TK05 did not develop graft vs. host disease (GvHD).
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FIGURE 2 | 18 F-FHBG-PET/CT scans of mice. Two NSG mice were
injected retro-orbitally with 2 × 106 of the same CD34-TK75 cells provided
to each patient. On days +7 and +27 each of these mice was paired with
an untreated mouse and they were simultaneously injected with the same
preparation of 18 F-FHBG that the patients received, then imaged 1 h later
using 18 F-FHBG microPET/CT. At this dose about half the mice get GvHD,
and only those mice had concentrated radiotracer in the thymic region
(circled).

will provide another metric to correlate therapeutic outcome with
ex vivo manipulations prior to infusion.
We noted that background 18 F-FHBG accumulation was negligible throughout the body in all human DLI recipients. In contrast,
it was difﬁcult or impossible to track CD34-TK75 expressing
human T cells trafﬁcking to the abdomen of mice due to the
high background accumulation of 18 F-FHBG in the abdomen.
As discussed earlier, a threshold level of radiotracer may be
required before it can be detected by imaging. Thus it is likely
that due to the very limited number of transduced T cells available for infusion (0.1–1.3 × 106 CD3/kg), we failed to reach that
threshold in any patient. Alternatively a diffuse distribution of
the transduced cells, an inappropriate choice of time points, or
a combination of these factors may have limited our ability to
detect an alteration in the pattern of uptake of 18 F-FHBG in
the tissues of human recipients after DLI. In collaboration with
MolMed we have initiated a second trial of 18 F-FHBG-PET/CT
imaging (IND14367, clinicaltrials.gov #NCT00914628) in which
patients that have poor immune recovery after haploidentical
transplant will be infused with TK transduced T cells from the
same haploidentical donor between 40 and 60 days post transplant. In this trial ≥50 times as many TK transduced cells/kg will
be administered.
A concern for long-term cell-based gene therapies is that
genetically modiﬁed cells might be immunologically recognized
and eliminated. Although patients in our trial exhibited neither a cellular nor serum immune response to CD34-TK75, an
immune response against unmodiﬁed TK has been noted in
other trials (reviews Berger et al., 2006; Traversari et al., 2007).
To address this concern investigators have developed mutated or
truncated versions of human mitochondrial TK 2 that should
be less immunogenic (Ponomarev et al., 2007; Campbell et al.,
2012), although they have not yet been tested in patients. GCV
used to treat cytomegalovirus infections, common after allogeneic
stem cell transplantation, can also eliminate TK-modiﬁed cells,
so other forms of CMV treatment and prophylaxis need to be
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considered if TK is the suicide gene chosen. GCV only kills
TK-bearing cells that are actively proliferating, so it is theoretically
possible that administration of the drug might fail to eliminate
all genetically modiﬁed cells. This might be advantageous in the
allogeneic transplant setting where the most proliferative alloreactive T cells would be preferentially eliminated leaving T cells
reactive to other antigens and the leukemia intact, thus enhancing the chances for immune reconstitution and a robust graft vs.
leukemia effect.
The biodistribution of 2 radioactive substrates used with
TK, 18 F-FHBG and 2 -deoxy-2 -[18 F]ﬂuoro-5-methyl-1-β-Darabinofuranosyluracil (18 F-FMAU), has been compared in
healthy volunteers (Campbell et al., 2012). More 18 F-FMAU than
18 F-FHBG accumulated in the liver, bladder, and myocardium
while more 18 F-FHBG than 18 F-FMAU was concentrated in the
gall bladder and gastrointestinal tract. This observation indicates
that one TK substrate for PET imaging may be preferable over
another depending upon the anticipated location of the genetically modiﬁed cells. This study also demonstrated that preclinical
models may not accurately reﬂect the distribution of the substrates
in humans since overall there was more background in mice when
using 18 FHBG than 18 F-FMAU, particularly in the gastrointestinal
tract, bladder, and spleen. In comparison, there was less overall
accumulation of 18 F-FHBG in patients than in mice, just as in the
study we report here. The reverse was true for 18 F-FMAU.
There are currently a number of suicide genes under preclinical
investigation. Developing additional highly retained radiolabeled
probes for imaging that have high signal to noise ratios could
be of signiﬁcant value to patients and the general biological
understanding in this ﬁeld.

PERSPECTIVE
Suicide genes such as TK should be considered an adjunct to any
clinical gene therapy trial in order to exploit their dual safety and
monitoring functions. Many factors govern which suicide gene
system is optimal. Among these are the anticipated urgency to
rid a patient of the cells, whether it is better to be able to leave
non-proliferating genetically modiﬁed cells intact or to kill all
transduced cells, the overall potency of a particular system, the
importance of bystander-cell killing, and immunogenicity. The
potential to gather safety or general biological information by
directly imaging the genetically modiﬁed cells in the patient should
be added to these considerations.
There are hurdles for performing any gene therapy trial.
Adding a component that requires synthesis of a radioactive probe
admittedly introduces additional complexities, but these are not
insurmountable. FDA and institutional oversight was required for
the cGMP quality manufacturing of both our genetically modiﬁed
cells and 18 F-FHBG, each of which required specialized facilities, highly trained individuals, and separate clinical protocols.
Nonetheless, because preclinical models do not always reﬂect the
biology of either healthy humans or patients, there is a marked
beneﬁt to including a tool to gather additional biologic information in a non-invasive manner. As transplant biology and
regenerative stem cell therapy advance, there is an increasing need
to monitor and understand the behavior of various exogenously
added cells in patients.
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